Kane Biotech Inc. V.KNE

News out - first paragraph copied below.

[cleareye]

2021-07-22 08:00 ET - News Release

 

WINNIPEG, Manitoba, July 22, 2021 (GLOBE NEWSWIRE) -- Kane Biotech Inc. announces plans to expand its wound care and surgical portfolio with an antimicrobial hydrogel based on its best-in-class coactiv+™ technology.

Kane has already demonstrated efficacy of its patented coactiv+^TM technology in both clinical studies to support various veterinary products and in large-scale consumer trials in support of the recently launched DermaKB^TM line of scalp care products. Use of the coactiv+^TM technology in wound care products will complement the company’s disruptive DispersinB^® wound care product development efforts whilst enabling the pursuit of the simpler 510(k) regulatory route and potentially quicker market access. Kane estimates the US market for wound care hydrogels to be approximately US$200M.

[MirrorWorldMan]

Announcing a plan to create a product is a long way from seeing it. That being said, Marc et al does have a reputation for getting stuff done and he is surrounded bu a capable group. It would be nice to remove some of the promotional fluff, size of the market etc and provide details on timing objectives and likely commercialization vectors.